Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions..Share Purchase Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • England
1INTERPRETATION 1 2GRANT 9 3ANCILLARY RIGHTS 9 4RIGHTS EXCEPTED AND RESERVED 13 5THIRD PARTY RIGHTS 15 6THE ANNUAL RENT 15 7SERVICES AND SERVICE CHARGE 15 8INSURANCE 20 9RATES AND TAXES 23 10UTILITIES 23 11COMMON ITEMS 24 12VAT 24 13DEFAULT INTEREST...Lease Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
Dated 23rd December 2017 The Management Team andDiscuva Limited TRANSFER INCENTIVE AGREEMENTTransfer Incentive Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
The Management Team have all provided support to the development of the Relevant Products of the Company and in recognition of this the Company has agreed to pay a transfer incentive payment to the Management Team in the event that the Relevant Products achieve certain milestones in their development and subject to the terms of this agreement.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DATED 20 September 2017Third Variation Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
EQUITY AND REVENUE SHARING AGREEMENT (Seeding Drug Discovery Initiative and Translation Award)Equity and Revenue Sharing Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • England
DATE [AGREEMENT DATE] Summit Therapeutics plc - and – [NON-EXECUTIVE DIRECTOR NAME] NON-EXECUTIVE DIRECTOR RESTRICTED STOCK UNIT (RSU) AGREEMENT (IN THE FORM OF A NOMINAL COST OPTION)Restricted Stock Unit Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations
WHEREAS the Company wishes to grant to the RSU Holder a restricted stock unit (RSU) in the form of a nominal-cost option on the terms set out in this Agreement, and this RSU is intended to comply with the requirements of Section 409A of the Code.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Contract • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations
AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) Ø RATING PAGE OF PAGES 1 63 2. CONTRACT (Proc. Inst. Ident.) NO.HHSO100201700014C 3. EFFECTIVE DATESee Block 20C 4. REQUISITION/PURCHASE REQUEST/PROJECT NO.OS202400 6. ISSUED BY CODE ASPR-BARDA 6. ADMINISTERED BY (If other than Item 5) CODE ASPR-BARDA02 ASPR-BARDAO’NEILL HOUSE OFFICE BUILDINGWashington DC 20515 US DEPT OF HEALTH & HUMAN SERVICESASST SEC OF PREPAREDNESS & RESPONSEACQ MANAGEMENT, CONTRACTS, & GRANTSO’NEILL HOUSE OFFICE BUILDINGWashington DC 20515 7. NAME AND ADDRESS OF CONTRACTOR (No., Street, City, County, State and ZIP Code) SUMMIT (OXFORD) LIMITED 1510803[**]; 85B PARK DRIVE85B PARK DRIVEMILTON PARKABINGDON OXFORDSHIRE OX14 8. DELIVERY ¨ FOB ORIGIN x OTHER (See below) 9. DISCOUNT FOR PROMPT PAYMENT 10. SUBMIT NOTICES(4 copies unless otherwise specified)TO THE ADDRESS SHOWN IN Ø ITEM CODE 1510803 FACILITY CODE 11. SHIP TO/MAKE FOR CODE HHS/OS/ASPR 12. PAYMENT WILL MADE BY CODE DHHS/FMS
LICENSE AND COMMERCIALIZATION AGREEMENT by and between SUMMIT (OXFORD) LTD and EUROFARMA LABORATÓRIOS S.A.License and Commercialization Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • New York
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”), effective as of December 18, 2017 (the “Effective Date”), is entered into by and between Summit (Oxford) Ltd, a limited company incorporated in England (with registered number 04636431) whose registered office is at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, United Kingdom (“Summit”) and Eurofarma Laboratórios S.A., a company incorporated in Brazil (with registered number 61.190.096/0001-92), whose principal place of business is at Avenue Vereador José Diniz, 3465, Campo Belo, São Paulo/SP, Brazil (“Eurofarma”).
